Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis

Cancer Prevention Research

Volumn 2, Issue 2, 2009, Pages 161-167

  Lubet, Ronald A ^a   Boring, Daniel ^a   Steele, Vernon E ^a   Ruppert, J Michael ^b   Juliana, M Margaret ^b   Grubbs, Clinton J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEXAROTENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; METHYLNITROSOUREA; MEVINOLIN; PROTEIN P53; TAMOXIFEN; TRIACYLGLYCEROL; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; RETINOID X RECEPTOR; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INCIDENCE; CARCINOGENESIS; CLINICAL EVALUATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG POTENTIATION; EPIDEMIOLOGICAL DATA; FEMALE; INCIDENCE; LIPOPHILICITY; LOW DRUG DOSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE H RAS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIET; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALKYLATING AGENTS; ANIMALS; ANTICARCINOGENIC AGENTS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL PROLIFERATION; DIET; DISEASE MODELS, ANIMAL; FEMALE; GENES, ERBB-2; HEPTANOIC ACIDS; LOVASTATIN; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RETINOID X RECEPTORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63249124558     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0134     Document Type: Article

References (33)

1. Lovastatin 5-year safety and efficacy studies. Lovastatin Study Groups I through IV. Arch Intern Med. 1993;153:1079-1087
2. Poynter J, Gruber S, Higgins P, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-2192
3. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825 (Pubitemid 46017933)
4. Cauley J, McTiernan A, Rodabough R, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-707 (Pubitemid 43821787)
5. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280-285 (Pubitemid 36513491)
6. Boudreau D, Yu O, Miglioretti D, et al. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-421
7. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942
8. Cox A, Der CJ. RAS family: signaling therapeutic targeting. Cancer Biol Ther 2002;1:599-606.
9. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000;5:187-200. (Pubitemid 32045695)
10. Chan M, Lu X, Merchant F, Iglehart J, Miron P. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis 2005;26:1343-1353 (Pubitemid 41417876)
11. Gottardis M, Bischoff E, Shirley M, et al. Chemoprevention of mammary carcinoma by LGD 1069 (targretin): an RXR selective ligand. Cancer Res 1996;56:5566-5570 (Pubitemid 26422151)
12. Suh N, Lamph W, Glasebrook A, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator arzoxifene, and a new rexinoid LGD 100268. Clin Cancer Res 2002;8:3270-3275 (Pubitemid 35155040)
13. Lubet R, Christov K, Nunez N, et al. Efficacy of targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis 2005;26:441-448 (Pubitemid 40246566)
14. Lubet R, Szabo E, Christov K, et al. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. Mol Cancer Ther 2008;7:972-979 (Pubitemid 351551051)
15. Lubet R, Gordon GB, Prough RH, et al. Modulation of methylnitrosourea- induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res 1998;58:921-926 (Pubitemid 28182459)
16. Lubet R, Christov K, You M, et al. Effects of the farnesyltransferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy and the role of HaRas mutations. Mol Cancer Ther 2006;5:1073-1078 (Pubitemid 43724608)
17. Huggins C, Grand LC, Brillantes FP. Mammary cancer induced by a single feeding of polycyclic hydrocarbons, and its suppression. Nature 1961;189:204-207
18. Siegal PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in the Neu proto-oncogene involved in the induction of mammary tumors. Mol Cell Biol 1994;14:7068-7077
19. Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53 and mouse mammary tumor virus. Exp Mol Pathol 2001;70:183-193 (Pubitemid 32607191)
20. Donehower LA, Harvey M, Slagle BL. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215-221
21. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated C-Neu oncogene. Cell 1988;54:105-115 (Pubitemid 18176767)
22. McGowan MW, Artiss JD, Strandbergh DR, Zax B. A peroxidases-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29:538-542
23. Peto J. The calculation and interpretation of survival cancers. In: Buyse ME, editor. Cancer clinical trials: methods and practice. Oxford Univ Press Oxford; 1966. p. 261-280
24. Armitage P. The chi-square test for heterogeneity of proportion after adjustment for stratification. J R Stat Soc B 1966;28:150-162
25. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4024 (Pubitemid 17108463)
26. Lubet R, Steele V, De Coster R, et al. Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345-1351
27. Jordan V. Chemoprevention with anti-estrogens: the beginning of the end for breast cancer. Ann NY Acad Sci 2001;952:60-72.
28. Wu K, Zhang Y, Xu C, et al. The retinoid x receptor-selective retinoid, LGD 1069, prevents the development of estrogen-receptor negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-6380
29. Grubbs C, Lubet R, Atigadda V, et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 2006;27:1232-1239 (Pubitemid 43985438)
30. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combinations of low doses of atorvastatin, aspirin and celecoxib in F344 rats. Cancer Res 2006;66:4542-4546
31. Shibata MA, Kavanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-459 (Pubitemid 36432640)
32. Denoyelle C, Albanese P, Uzan G, et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 2003;15:327-338 (Pubitemid 36071677)
33. Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53 independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004;25:1887-1898 (Pubitemid 39405908)